Haematological Malignancy Diagnostic Service, St. James's Institute of Oncology, Bexley Wing, Beckett Street, Leeds LS9 7TF, UK.
Best Pract Res Clin Haematol. 2010 Mar;23(1):61-9. doi: 10.1016/j.beha.2010.02.002.
Monoclonal B-lymphocytosis (MBL) is defined as the presence of a population of monoclonal B-cells, usually with a chronic lymphocytic leukaemia (CLL) phenotype, which comprise fewer than 5000 cells per microl with no evidence of tissue involvement. Over the past few years, MBL has been clearly defined and differentiated from CLL so that individuals with MBL are no longer inappropriately labelled as suffering from leukaemia. In this review, we will describe the entity of MBL and summarise the evidence that underlies the current theory on the pathophysiology of the disorder, the relationship with CLL and the probability of developing progressive disease requiring treatment. In addition, we will evaluate the importance of further clinical investigations, in particular, the relevance of screening for MBL and undertaking bone marrow investigations according to the clinical setting and B-cell phenotype.
单克隆 B 淋巴细胞增多症（MBL）定义为单克隆 B 细胞群体的存在，通常具有慢性淋巴细胞白血病（CLL）表型，每微升少于 5000 个细胞，无组织受累证据。在过去的几年中，MBL 已经得到了明确的定义和区分，与 CLL 不同，因此，MBL 患者不再被不恰当地贴上患有白血病的标签。在这篇综述中，我们将描述 MBL 的实体，并总结当前关于该疾病病理生理学的理论基础、与 CLL 的关系以及发展为需要治疗的进行性疾病的可能性的证据。此外，我们将评估进一步临床研究的重要性，特别是根据临床情况和 B 细胞表型筛查 MBL 和进行骨髓检查的相关性。
